Trials / Completed
CompletedNCT04110054
Evaluation of S-600918 in Adults With Refractory Chronic Cough
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 406 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-600918 | Tablets for oral administration |
| DRUG | Placebo to S-600918 | Tablets for oral administration |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2020-12-08
- Completion
- 2020-12-28
- First posted
- 2019-10-01
- Last updated
- 2024-03-27
- Results posted
- 2024-03-27
Locations
136 sites across 6 countries: United States, Czechia, Japan, Poland, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04110054. Inclusion in this directory is not an endorsement.